Avadel Pharmaceuticals plc
NASDAQ:AVDL 4:00:00 PM EDT
| Market Cap (Intraday) | 1.27B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | 21.64 |
| 10-Day MA | $13.01 |
| 50-Day MA | $14.36 |
| 200-Day MA | N/A |
Avadel Pharmaceuticals plc Stock, NASDAQ:AVDL
10 Earlsfort Terrace, Block 10-1, 2nd Floor, Dublin, Dublin 02
Ireland
Phone: +353.1.901.5201
Number of Employees: 154
Description
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.